Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions

Area of Science:

• Neuroscience
• Molecular Biology
• Psychiatry

Background:

• Epigenetics regulates gene expression via mechanisms independent of DNA sequence, primarily through chromatin histone modifications.
• Emerging evidence suggests epigenetic alterations contribute to the pathophysiology of mood disorders, including bipolar disorder (BD) and major depressive disorder (MDD).
• Histone deacetylase (HDAC) inhibitors influence epigenetic programming, impacting cognition and behavior, and may reverse early life stress-induced epigenetic dysregulation in preclinical models.

Purpose of the Study:

• To explore the potential of targeting chromatin remodeling and gene promoter accessibility as a therapeutic strategy for mood disorders.
• To investigate the role of histone deacetylase (HDAC) inhibitors, such as valproate (VPA), in modulating the epigenome for mood disorder treatment.
• To highlight the need for further research into the therapeutic potential and limitations of HDAC inhibitors in managing mood disorders.

Main Methods:

• Review of existing literature on epigenetics, mood disorders, and HDAC inhibitors.
• Analysis of preclinical findings on HDAC inhibition and reversal of epigenetic dysregulation.
• Examination of valproate (VPA) as a mood stabilizer with HDAC inhibitory properties.

Main Results:

• Chromatin adaptation and gene promoter accessibility are identified as potential therapeutic targets for mood disorders.
• Valproate (VPA), a mood stabilizer, demonstrates epigenetic modulation through HDAC inhibition.
• Limitations of current HDAC inhibitors include lack of isoform selectivity and potential for serious side effects.

Conclusions:

• Epigenetic mechanisms, particularly chromatin remodeling, represent a promising area for novel therapeutics in mood disorders.
• While VPA shows potential, the non-selective nature of HDAC inhibitors necessitates further investigation into targeted approaches.
• Clarifying the role of chromatin remodeling in antidepressant and mood stabilizer action is crucial for developing safer and more effective treatments for BD and MDD.